A Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel for the Improvement of Skin Quality in Adult Participants

Last updated: March 4, 2025
Sponsor: AbbVie
Overall Status: Completed

Phase

2

Condition

N/A

Treatment

ELAPR002f Injectable Gel

Clinical Study ID

NCT06151535
2028-601-008
  • Ages 30-60
  • All Genders

Study Summary

Elastin is a protein found in the dermis of the skin that is gradually lost with aging which impacts skin tissue and leads to reduced structural integrity, hydration, and elasticity of the skin, resulting in loose skin and the formation of folds and wrinkles. Loose skin, folds, and wrinkles can be treated by injecting biocompatible structures to fill the the affected area and improve elasticity/hydration upon implantation. The purpose of this study is to evaluate the safety and effectiveness of ELAPR002f injectable gel in adult participants for the improvement of skin quality in adults.

ELAPR002f injectable gel is an investigational device being developed for the improvement of facial skin quality attributes such as fine lines, elasticity, and hydration. Approximately 30 participants 30 to 60 years of age seeking improvement of skin quality will be enrolled.

Participants will receive 3 treatment sessions, 1 month apart, of ELAPR002f injectable gel to each cheek and behind 1 ear (for histological assessment) and will be followed up for up to 4 months.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Participants in general good health, in the opinion of the investigator, with noknown active COVID-19 infection, seeking improvement of facial skin quality.

  • Moderate or severe (symmetric grade 2 or 3 on the Allergan Fine Lines Scale [AFLS]and Allergan Cheek Smoothness Scale [ACSS]) fine lines and cheek smoothness scoreson both cheeks based on investigator's live assessment.

  • Each cheek is amenable to at least a 1 point improvement on the AFLS and ACSS.

Exclusion

Exclusion Criteria:

  • Current cutaneous or mucosal inflammatory or infectious processes (eg, herpes),rosacea, abscess, an unhealed wound, active acne, or a cancerous or precancerouslesion, on the face or behind the ears.

  • History of pigmentation disorders or current pigmentation disorder on the face orbehind the ears.

  • Active smoker.

  • Currently using topical retinoids, or have used topical retinoids in the past 60days (2 months) on the face or behind the ears.

Study Design

Total Participants: 30
Treatment Group(s): 1
Primary Treatment: ELAPR002f Injectable Gel
Phase: 2
Study Start date:
December 19, 2023
Estimated Completion Date:
February 24, 2025

Connect with a study center

  • CRC - Centro Ricerche Cliniche di Verona S.r.l. /ID# 226370

    Verona, 37134
    Italy

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.